Wuhan Sian Medical Technology Co.Ltd
Second generation CAR-T cells(Wuhan Sian Medical Technology Co., Ltd)은 Acute Lymphoblastic Leukemia 표적 세포·유전자 치료로, Acute Lymphoblastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting a human tumor-specific antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 46건의 관련 임상이 등록되어 있습니다. 차별점: novel strategy to ameliorate the prognosis of glioma patients.
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; B Cell Lymphoma
Active
CAR T cell-mediated xenogeneic graft versus host disease in NSG m
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized xenograft model and showed no evidence of significant off-target toxicity in immunocompetent hosts
novel strategy to ameliorate the prognosis of glioma patients
targeting a human tumor-specific antigen
T cells containing co-stimulatory structural domains, and co-stimulatory molecules are critical for CAR-T cell activation
apoptosis, and significantly extended survival of mice bearing patient-derived GBM, with no evidence of off-tumor toxicity
Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis
downregulation and impaired CD4 + T cell help, but also successfully develops ADV-ICOSL to reverse this limitation
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Wuhan Sian Medical Technology Co.Ltd
Second generation CAR-T cells(Wuhan Sian Medical Technology Co., Ltd)은 Acute Lymphoblastic Leukemia 표적 세포·유전자 치료로, Acute Lymphoblastic Leukemia; B Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting a human tumor-specific antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 46건의 관련 임상이 등록되어 있습니다. 차별점: novel strategy to ameliorate the prognosis of glioma patients.
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia; B Cell Lymphoma
Active
CAR T cell-mediated xenogeneic graft versus host disease in NSG m
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized xenograft model and showed no evidence of significant off-target toxicity in immunocompetent hosts
novel strategy to ameliorate the prognosis of glioma patients
targeting a human tumor-specific antigen
T cells containing co-stimulatory structural domains, and co-stimulatory molecules are critical for CAR-T cell activation
apoptosis, and significantly extended survival of mice bearing patient-derived GBM, with no evidence of off-tumor toxicity
Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis
downregulation and impaired CD4 + T cell help, but also successfully develops ADV-ICOSL to reverse this limitation
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.